220 related articles for article (PubMed ID: 35586006)
1. Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study.
Flacco ME; Soldato G; Acuti Martellucci C; Di Martino G; Carota R; Caponetti A; Manzoli L
Front Public Health; 2022; 10():884121. PubMed ID: 35586006
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
3. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.
Cegolon L; Magnano G; Negro C; Larese Filon F;
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515237
[No Abstract] [Full Text] [Related]
5. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.
Vicentini M; Venturelli F; Mancuso P; Bisaccia E; Zerbini A; Massari M; Cossarizza A; De Biasi S; Pezzotti P; Bedeschi E; Giorgi Rossi P; ;
Euro Surveill; 2023 Mar; 28(13):. PubMed ID: 36995374
[TBL] [Abstract][Full Text] [Related]
6. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
7. Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis.
Flacco ME; Acuti Martellucci C; Baccolini V; De Vito C; Renzi E; Villari P; Manzoli L
Eur J Clin Invest; 2022 Oct; 52(10):e13845. PubMed ID: 35904405
[TBL] [Abstract][Full Text] [Related]
8. Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022.
Bøås H; Storm ML; Tapia G; Kristoffersen AB; Løvlie AL; Størdal K; Lyngstad TM; Bragstad K; Hungnes O; Veneti L
BMC Public Health; 2024 Jan; 24(1):181. PubMed ID: 38225588
[TBL] [Abstract][Full Text] [Related]
9. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
[TBL] [Abstract][Full Text] [Related]
10. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.
Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Gilca R; Ouakki M; Barkati S; Fafard J; Talbot D; Gilca V; Deceuninck G; Garenc C; Carignan A; De Wals P; De Serres G
JAMA Netw Open; 2022 Oct; 5(10):e2236670. PubMed ID: 36239934
[TBL] [Abstract][Full Text] [Related]
11. Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia.
Medic S; Anastassopoulou C; Lozanov-Crvenkovic Z; Dragnic N; Petrovic V; Ristic M; Pustahija T; Tsakris A; Ioannidis JPA
JAMA Netw Open; 2023 Feb; 6(2):e2255779. PubMed ID: 36780157
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 reinfection with Omicron variant in Shaanxi Province, China: December 2022 to February 2023.
Zhang M; Cao L; Zhang L; Li X; Chen S; Zhang Y
BMC Public Health; 2024 Feb; 24(1):496. PubMed ID: 38365671
[TBL] [Abstract][Full Text] [Related]
13. Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study.
Jang EJ; Choe YJ; Yun GW; Wang S; Cho UJ; Yi S; Lee S; Park YJ
J Med Virol; 2022 Nov; 94(11):5589-5592. PubMed ID: 35879105
[TBL] [Abstract][Full Text] [Related]
14. Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
Chemaitelly H; Nagelkerke N; Ayoub HH; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36179099
[TBL] [Abstract][Full Text] [Related]
15. Incidence and severity of SARS-CoV-2 reinfection, a multicenter cohort study in Shanghai, China.
Yu W; Guo Y; Hu T; Liu Y; Fan Q; Guo L; Zheng B; Kong Y; Zhu H; Yu J; Chen S; Zhang Y; Wang J; Li F; Yang F; Wang Y; Zhu Y; Huang Y; Shen Z; Ruan Y; Mao R; Zhang J
J Med Virol; 2023 Aug; 95(8):e28997. PubMed ID: 37537950
[TBL] [Abstract][Full Text] [Related]
16. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.
Wei J; Stoesser N; Matthews PC; Khera T; Gethings O; Diamond I; Studley R; Taylor N; Peto TEA; Walker AS; Pouwels KB; Eyre DW;
Nat Commun; 2024 Feb; 15(1):1008. PubMed ID: 38307854
[TBL] [Abstract][Full Text] [Related]
17. An ecological study on reinfection rates using a large dataset of RT-qPCR tests for SARS-CoV-2 in Santiago of Chile.
Acuña-Castillo C; Barrera-Avalos C; Bachelet VC; Milla LA; Inostroza-Molina A; Vidal M; Luraschi R; Vallejos-Vidal E; Mella-Torres A; Valdés D; Reyes-López FE; Imarai M; Rojas P; Sandino AM
Front Public Health; 2023; 11():1191377. PubMed ID: 37492136
[TBL] [Abstract][Full Text] [Related]
18. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.
Pilz S; Theiler-Schwetz V; Trummer C; Krause R; Ioannidis JPA
Environ Res; 2022 Jun; 209():112911. PubMed ID: 35149106
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection.
Lewis N; Chambers LC; Chu HT; Fortnam T; De Vito R; Gargano LM; Chan PA; McDonald J; Hogan JW
JAMA Netw Open; 2022 Jul; 5(7):e2223917. PubMed ID: 35895058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
